Back to News
Feb 5, 2026 12:01 PM

Eli Lilly Beats Q4 Estimates But Shares Slide: Analyst Expects 'Clear Runway Into Next Decade'

Although Eli Lilly And Co (NYSE:LLY) reported its fourth-quarter revenues and earnings ahead of consensus estimates, backed by higher sales of Zepbound and Mounjaro, according to Scotiabank.

The Eli Lilly Analyst: Analyst Louise Chen maintained a Sector Outperform rating, while raising the price target from $1,165 to $1,300.

The Eli Lilly Thesis: The company reported sales and earnings of $19,292 million and $7.54 per share, topping consensus estimates of $17,944 million and $6.91 per share, respectively, Chen said in the note.

Check out other analyst stock ratings.

Zepbound sales came in at $4,261 million, higher than ...